Sildenafil
Product Images NDC 50090-4646

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 50090-4646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904646)

Sildenafil 50 mg tablet label by A-S Medication Solutions featuring product number 6803-0 and NDC 50090-4646-0. The label states each tablet contains sildenafil citrate equivalent to 50 mg sildenafil USP. Storage instructions recommend 68 to 77 degrees Fahrenheit. Package contains 10 tablets with a dosage instruction to see package insert.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 1)

Chemical structure diagram of the active ingredient sildenafil, showing its molecular components and connectivity as typically presented in pharmaceutical labeling documents.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 2)

A line graph comparing systolic blood pressure (mmHg) changes over 24 hours between Sildenafil 100 mg and placebo. The x-axis represents time post dose in hours, and the y-axis shows systolic blood pressure change. Sildenafil and placebo show different pressure trends over time.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 3)

A line graph depicting change in systolic blood pressure (SBP) over 8 hours post dose, comparing Doxazosin with Placebo versus Doxazosin with Sildenafil 25 mg. The y-axis shows change in SBP (mmHg), ranging approximately from -40 to +20, and the x-axis shows time post dose in hours from 0 to 8.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 4)

Line graph showing the change in systolic blood pressure (SBP) in mmHg over time post dose (hours) for two groups: Doxazosin with Placebo and Doxazosin with Sildenafil 50 mg. The x-axis represents time post dose from 0 to 8 hours, and the y-axis represents change in SBP from -50 to 40 mmHg, indicating fluctuations in blood pressure following dosing.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 5)

A line graph showing the effect over time (0 to 8 hours) after dosing on mmHg blood pressure. Two lines represent Doxazosin combined with Sildenafil 100 mg and Doxazosin combined with Placebo, respectively, tracking changes in blood pressure from 0 to -50 mmHg over the time course.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 6)

A line graph displaying plasma concentrations (ng/ml) over time post dose (hours) for Sildenafil tablets. The graph shows an initial rapid increase in plasma concentration, peaking around 1 hour, followed by a gradual decline over a 24-hour period. The data points represent the commercial tablet formulation.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 7)

A bar chart illustrating the effect of sildenafil on maintenance of erection by baseline score. The x-axis represents baseline scores from 0 to 5, and the y-axis represents the percentage of patients at endpoint, ranging from 0 to 80%. Different bars correspond to scores from 0 to 5, showing patient distribution across varying baseline scores.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 8)

A bar chart titled 'Effect of Placebo on Maintenance of Erection by Baseline Score' illustrating the percentage of patients at endpoint on the y-axis and baseline score on the x-axis from 0 to 5. Multiple bars for each baseline score represent different categories ranging from 0 to 5, showing variation in patient response percentages at each baseline level.*

FDA Label Image

10 (Sildenafil Tablets 25 50 100 9)

A bar graph depicting the percentage of patients reporting improvement across different treatment groups: Placebo (24%), Sildenafil 25 mg (63%), Sildenafil 50 mg (74%), and Sildenafil 100 mg (82%). The x-axis represents treatment groups, and the y-axis shows the percentage of patients reporting improvement, with an overall treatment p-value of less than 0.0001.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.